NCT06713590View on ClinicalTrials.gov

A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

72

Participants

Timeline

Start Date

January 14, 2025

Primary Completion Date

June 6, 2025

Study Completion Date

June 10, 2025

Conditions

Healthy Participants

Interventions

DRUG

Axatilimab

Axatilimab will be administered at protocol defined dose.

Trial Locations (1)

85283

Celerion, Inc, Tempe

Sponsors

Lead Sponsor

Incyte Corporation

All Listed Sponsors

lead

Incyte Corporation

INDUSTRY